We review the literature on nasopharyngeal carcinoma that has been publish ed within the pa st 5 years. Na sopharyngeal carcinoma is a highl y morbid dis ease, and survival ispoor:
Introduction
Nasopharyngeal carcinoma is a rare tumor that arises in the epithelium of the nasopharynx . It accounts for more than 95 % of nasopharyngeal malignancies in adults and 20 to 35% of nasopharyngeal malignancies in children. I It is often misdi agn osed earl y becau se of the vagueness of the presenting sy mptoms and the difficulty of the nasopharyngeal examination.
Anatomy
Th e nasoph arynx is a trapezoid chamb er located posteri or to the nasal choa nae; it extends inferiorly to the lower border of the soft palate. Th e super ior border is form ed by the basisph enoid and basiocc iput. Th e posterior border is made up of the prevertebral fasc ia of the atlas and axis. Th e pharyn goba silar fasci a, which is the only soft-tissue bord er, form s the late ral wall s of the nasopharynx. The eustachian tubes traver se this fascia bilaterally.The eustachian tube s are covered superiorly and posteriorly by cartilage (the toru s tubarius). Th e fossa of Rosenmtiller, which is located superior and posterior to the toru s tubarius, is an important landmark becau se it is the most common site of origin for nasopharyngeal carcin oma.'
Histology
At birth , the nasoph arynx is lined with a predominantly pseud ostratified columnar epi thelium. Over the first 10 years of life, this epithelium grad ually tran sform s into a predomin antl y stratified, nonkeratinizing squamous epithelium , exce pt in a few areas (tra nsition zones) .
Epidemiology
Th e incidence of nasoph aryn geal carc inom a in the United Stat es and Europ e is only about I per 100,000 popul ation , but in Taiwan, Hon g Kon g, and southern China (especially Guan gdon g province), the incidence is approximately 30 times higher/The risk of nasoph aryngeal carcinoma in any given area rises when Chin ese genes are introduced into the area . The incidence among Africans and Filipinos is approximately 2 t04 per 100,000 population.' Nasopharyngeal carcinoma is more common in males by a margin of about 2 to 1. 1 Its incid enc e peak s at 50 to 60 years of age; a small peak also occurs durin g late childhood. I Genetic analysis of end emic populations has revealed that the association of HLA-A2, HLA-B17 , and HLA-Bw26 doubl es the risk ofnasoph aryngeal carcin omaThese HLA associations are not see n in North Amer ica.
Another important etiologic factor in so me type s of naso pharyngeal carc ino ma is the Epstein-B arr virus (EBV). Th e detection of the EBV nuclear antige n and viral DNA in nasopharyngeal carcin oma has revealed that EBV can infect epithelial cells and that it is associated with their transformation to canc er. Clonal EBV DN A has been found in so me prein vasive lesions, suggesting a relationship to the transform ation proc ess.
Other association s includ e chronic nasal infections, poor hygien e, poor ventilation of the nasopharynx, and expo sure to the nitros amin es and polycyclic hydrocarbons in salt-preserved food s.
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Clinical presentation
Nasophar yngeal carcin om a rar el y comes to medi cal attention before it has spread to reg ional lymph nodes. Skinner et al found that a unilateral neck ma ss was the mo st common presenting sig n, occ urring in 36 % of cases.'
Other authors ha ve repor ted rates as high as 80 % .1 Oth er presenting sig ns and sympto ms include blood-stain ed nasal discharge (I 8% of cases) , uni lateral hearin g loss ( 12%), and unilateral nasal obstructio n (5%) . 4 Crani al ner ve involv ement subsequent to invasion of the skull ba se is see n in 25% of cases.' The two principal cranial ner ve syndromes associated with nasopharyngeal carc inom a are retropa rotid syndrome (invo lving cranial nerves IX , X, XI, and XII ) and petrosphenoid syndrome (involving cranial ner ves III, IV, V, and VI). Occ asion ally, cranial ner ve II becom es involved through the foramen lacerum. Typ ically, nasoph aryn geal carcino ma carries a poor prognosis becau se of its pro ximity to vital structures , its invasiv en ess, the subtlety of its sy mptoms, and the difficult nature of the examination, es pecially for prim ary care physician s. Rates of distant meta sta sis at present ation are 3% in the Un ited State s and up to 6% in ende mic areas of the world.'
Pathology
In 1979 , the World Health Or gani zati on (W HO) defin ed three types of nasopharyngeal carcin oma on the basis of findin gs on light micro scop y."
Type I. Thi s keratinizing squa mo us cell ca rcino ma is ch aracterized by the presenc e of intracellul ar brid ge s and prominent keratin formati on . Type I tumors acco unt for appro ximate ly 25% of all nasopharyngeal ca rcinom as in North Am erica but only I% of cases in ende mic areas.'
Patients with typ e I disea se ha ve the wors t progn osis, as the 5-ye ar sur viva l rate is onl y 35 %. 3 Type II. Thi s tumor exhibits the matur ation sequence characteristic of squa mous cell carcinoma but no keratin for mation.' Thi s is the least co mmo n of the three typ es, and it is often classifi ed as type III. The 5-year surv ival rate is 6 I% .3 Type III. Thi s und ifferentiated carcinoma is mad e up of cells of varyin g morphology, and it frequen tly co ntai ns clumps ofbeni gn T cell s intermi xed within the tum or mass; as a result, it is also call ed a lymph oepithelioma? Type III tumors acc ount for 95 % of all cases in ende mic areas and 60 % of cases in North Ame rica . The 5-year survival rate is 6 1%. 3 Rat es of distant metastasis are higher in patient s with type II or III tumors than in pati ent s with typ e I tumors. On the oth er hand, type II and III tumors are more eas ily co ntro lled, owing to their grea ter degree of radi osen siti vity, and therefore patien ts with type II or III disease have a bette r prognosis.
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Diagnosis
Th e diagn osis of nasopharyn geal carcm orna is based prim aril y on the history and physical examinat ion. Ob viously, a de finiti ve diagnos is requires a biop sy of the lesion, either in the office or in the operating room. Th e prefer red imaging modalities are computed tom ography (CT) with contrast and ma gnetic reso nance imagin g (MRI) with enha nce ment. Most onc olog y texts appea r to favor MRI over CT be ca use it pro vides more det ail s on ex tension and intracranial invol vement. On the othe r hand , CT dem onstrates more evi dence of bony erosion. These fac tors are all important in the stag ing of the d isease.
Staging
Approximately 20 different stagi ng sys tems for nasopharyn geal carcinoma have been reported in the literature since the early I950s. 7 John Ho , a preeminent radiation oncologist, de veloped a stag ing sys tem in the late I960s that was used for many years." Ho 's sys tem , whi ch is based on the natural history of the disease and autopsy obse rvations, is still used in China, but it has been rep laced by more standa rdized systems elsewhere. Even so, the systems that have repl aced Ho 's have var ious inad equacies of their own . In 1989 , for ex ample, Neel and Taylor used Cox regression methods to identi fy five disea se-related characteristi cs that were significantly associated with survival, but their sys tem was not adopted by man y inst itut ion s bec ause its criter ia we re completely different fro m ex isting sys tems that had been used to stage nasoph ar yn geal cancers ." Th e maj or draw back of the system published by the Am erican Joint Committee on Cancer (AJCC) in 1992 was the unevenness of the pati ent distr ibution-specifically, too man y pati ents were pooled into stage IV.10The AJCC subseque ntly improved the distribution of patient s and adopt ed so me of Ho 's progno stic cri ter ia (e.g ., the involvement of the supraclavicular fossa), and in 1997 11 and 2002, 12 it published upd ated guidelines tha t are standard in mo st institutions. Th e wid espread acc eptance of the new est AJCC sys tem (tables I and 2) has mad e it much eas ier to compare out comes in differ ent centers .
Molecular markers
Mo st tum or markers are proteins found in plasma or serum that have some degree of spec ificity for a part icular tum or. Prot ein s are used as markers partly because of their relatively high concentrations in serum and plasma and bec ause of the ready availability of immunologi c meth od s (e.g., radio immunoassay and enzyme-linked imrnunosorbent ass ay) that provide rapid and acc urate quan tification of markers. With a potentially superior therapeuti c index , molecular markers repres ent an ex citing ad vance in that they can be used to generate immunoth erapy that will co mpleme nt conventional chemotherapy.!' M arker s for nasoph aryng eal carc inoma includ e p53 , N3a Nod e is large r than 6 cm N3b Metastasis to the supraclavicular fossa is present epidermal growth fac tor receptor (EGFR), angiogenic fac tors, EBV, proliferating ce ll nuclear antigen , Ki-67, and c-er blsz ." Gen e et al showed that altho ug h p53 pos itiv ity co rrelated with the presence of lymph node disease, it was not a significant fac tor in predicting outco me .IS Stud ies by Chua et aP6 and Leong et al" showed that expression of EGFR was increased in nasoph aryngeal carcinoma . T his findi ng paved the way for a phase II study of cetuximab in co mbinatio n wit h ca rbo platin." T he overall response rate was 17%, and the rate of partial response or stab le disease was 66 % . EGFR may be a viable target for furt her clinical trials. Vascular endo the lial growth fac tor (VEGF) is an angioge nic factor. G ua ng-Wu et al reported that VEGF was ex pressed in 10% of subjects who had a normalnasoph arynx, in 40 % of patie nts who had a ben ign tumor of the naso phary nx, and in 80% ofthose who had nasopharyngeal carc inoma." Th ey also reported tha t expression of VEGF was eve n high er in patients with advanced nasopharyngeal carc inoma. Despite these findings, the ro le of VEGF as a potent ial target has ye t to be exp lored.
EBV DN A seems to show promise as a marker to mo nitor and pred ict treat ment outcomes in pa tie nts with adva nce d nasoph aryngeal carcino ma. In 2003, Lin et al reported their study of 99 pat ients wi th stage III or IV disease who had been treated wi th neoadju vant chemothera py followed by radi ation ." At basel ine, 94 of these pa tients, incl uding all patient s wit h metastatic disease, had de tectab le levels of 170 T2  T3  T4   NO   I  II  III  IV   N1   II  II  III  IV   N2   III  III  III  IV   N3   IV  IV  IV  IV EBV DNA in plas ma ; none of the disease-free co ntro ls had detectable EBV DNA . T he role of imm unotherapy based on EBV latent me mbra ne protei ns is under study.
Treatment
Radiotherapy. It was not unt il the 1920s tha t radiation therapy was co nside red for nasopharyngeal carcinoma. The early reluctance to irra diate the naso pharynx was attr ibutab le to its prox imi ty to other radiatio n-se ns itive struc tures, suc h as the eye an d sp ina l cord, as we ll as to the poor dep th of pene tration of x-rays at that time . In the ea rly 1920s, the first intercavitary treatme nt with radium was performed at the Institu t Curie in Pa ris . Th is brachytherapy co nti nues to be used in some places today for the treatm ent of primary T I and T2 tumor s th inner than IOrnm, altho ugh rad ium has been rep lace d by iridium 192 . 14 Until 1977 , the sta ndard of care for nasoph aryn geal carci noma in No rth Amer ica was sta ndard frac tionated radiation therapy." Typical radiation fields enco mpass the adjacent sk ull base and the nasopharyn x. Fie lds are bilaterall y di rected and inclu de the ret ropharyngeal dra inage path way and the anter ior and posterior cervical cha ins." Patie nts with stage I or II nasoph aryn geal carcinoma have a high rate of cure with radiothera py alone, but the progn osis for those with distant metastasis is poor. Tum or contro l has bee n highly correlate d with the amo unt of radiat ion del ivered to the tum or. In a review of 13 rand omi zed trials wit h similar dosing by Agu lnik and Siu, most of the studies invol ved the use of a split-fie ld tec hnique, wit h two lateral opposed fac ial field s and an anter ior field if necessary." In order to achieve tumor co ntro l, a dose of mo re than 67 Gy is requ ired ; local co ntro l ca n be fur ther improved by mai ntai ning tech nica l accuracy during rad iatio n de livery. "
In 1998, the use oft hree -di mensio nal intensity-mod ulated radiation therapy (IM RT) was initiated at Me mor ial Sioan-Kettering Cancer Ce nter for the treat ment ofnasopharyngeal carci noma ." A 2-year follow -up of 39 of these patients revealed a local relapse -free survival rate of97 %, co mpared with a rate of only 78 % amo ng histor ica l co ntrols." Similar studies in San Franc isco and Ho ng Ko ng dem on strated the local benefits of IMRT, as we ll as its favo rab le tox icity profile." Of note, no large rand om ized trial co mpa ring IMRT with co nve ntio na l two-or three-dim ension al radiation techn iques has been co mpleted.
To help us determine the optima l radia tion regi men, authors must clearly report total radia tion doses, doses per frac tion, and target volume dose var iations.
Chemotherapy. Chemotherapy was first used in the 1970s as a co mponent of primary curative treatment. 1-1 Chemotherapy is classified into three ca tego ries based on when it is deli vered in relation to radiothera py : neoadjuvant, concurrent , and adj uvant. Chemotherapy acts as a radiosensitizer, and it helps decrease the rate of distant metastasis.
In 1998, Intergroup study 009 9 was publi shed by AI-Sarraf et al." Thi s study showed that patients who were treated with radiation alone had a significantly lower f-year survival rate (46 %) than did patient s who received radiation with concurrent cisplatin chemotherapy followed by additi onal chemotherapy with cisplatin and 5-fluorou racil (76%). Thi s study changed the standa rd of care in the United States, even though it has been criticized becau se ( I) the investigators used the 1992 AlCC stagi ng criter ia and therefore treated some early-stage nasopharyngeal carcinomas; (2) only about 45% of patients had WHO stage III ca ncer; (3) the radiothera py techniques used at different institutio ns were not uniform, which acco unted forthe poor result s see n in the radiotherapy-alone arm; and (4) compliance wi th chemotherapy was poor (only 55 to 73%).20 Furth ermore, prior to 2004, 13 phase III randomized com parisons of radiation alone with concurrent and/or adj uvant chemotherapy had been published in the literature, and Intergroup study 0099 was the only one to show that comb ined therapy res ulted in a positiv e outcome."
As a result ofthese cr iticisms, co mbined-modality treatment for advanced nasoph aryngeal carcinoma has not been accepted to a significa nt extent in end emic southeastern Asia. However, some of these 13 previou sly published trial s had shortcomings of their own . For example, Rossi et al included many patients who were at low risk for distant metastasis whil e using a less-acti ve combination of vincristine, cyclophosphamide, and doxorubi cin ." Chi et al used adj uva nt cisplatin, 5-fluoro urac il, and leucovorin and noted no benefit in surv ival, but their patient s ex perienced an unusually high numb er of treatm ent-relat ed deaths in the com bination arm and an interm edi ate risk of relapse in one of their cohor ts." Hareyarna et al found no benefit to using neoadjuva ntchemot herapy, but their study was small, they included patient s with ea rly-s tage disease, and their chemotherapeutic dosages were low." Finally, an Asian-Oceanian Clinical Oncology Assoc iation study" involved a relatively low dose of cisplatin , and an International Nasopharynx Canc er Stud y Group trial" was marked by a significant numb er of patients who refused radiotherapy and a large numb er of chemotherapy-re lated death s.
Th e first study to show any benefit to concurrent chemotherapy in an end emic area was the 2003 study by Lin et al,2l)The structure of this study was simil ar to that 172 of Intergroup study 00 99. 21 Patients rece ived concurrent cisplatin and a lower dose of 5-fluoro urac il. Th e 5-year disease-free survival rate was 89% in the co mbinatio n ar m, co mpared with 73% in the radiatio n-o nly arm-a sta tistically significant difference."
In summary, the conflicting results in the literature make it difficult to develop a chemotherapeutic regi men-or eve n to determine that chemotherapy co nfers any benefit at all. Th e difficult y is comp ound ed by the use of different staging sys tems and study protocols. For example, so me studies are not rand omi zed, and some have small sa mple sizes. In many publi shed series, authors have not specified rates of distant metastases or indicated whether the metastasis was the first or only site of failure ; it is important that thes e data be interpreted in relation to the WHO classification becau se types II and III are associated with higher rates of distant metasta sis. Finally, we have not identified the optimum numb er of chemotherapy cycles . We do know that the timin g of che mothera py appears to have an impact on clini cal outco me and that the dose intensity is best maint ained in the induction setting. In the 13 randomized trials reported by Agulnik and Siu , the disparity in dose intensities may parti ally ex plain the lack of benefit associated with adj uva nt chemo therapy. 13 More trials on chemora diat ion are required to determin e the optimum chemotherapeutic age nts and schedule that ca n be used with radi ation therapy to ac hieve better treatment results.
Surgery. Surg ery has a limited role in the treatm ent of nasoph aryngeal carcinom a because of the tumor's high degree of radio sen sitivity and the anatomi c barriers to surg ical access . Th e role of the surgeon is usually limited to obtaining tissue for diagnosis, occa sionally resecting residual adenopathy afte r definitiv e radiotherapy, and providin g symptomatic relief (e.g., placement of tyrnpanostomy tubes).
Variou s surgical approaches have been describ ed in the literatur e, including transpalatal , transmaxillary, midline mandibulotomy, facial degloving, infratemp oral fossa, and endosco pic approac hes ." Surgery is associated with slightly better control and a lower rate of complications than repeat irradiation in patients with limited disease. Surgery is typically co ntra indica ted for patients with any evidence of extension into the paraph aryngeal space , skull base, paranasal sinuses, or caro tid artery because of surgery 's high deg ree of morb idity and the low pro bability of effec ting a cure.
Fee et al describ ed a combination transpalatal , transmaxillary, and transcer vical app roach in 33 patients with rec urre nt nasoph aryn geal carcinoma." Th ey ach ieved a 5-year local control rate of 67 % and an overall surv ival of 60 %. Fisch et aP I describ ed the infrat emp oral approach, and Panje et aP2 de scribed the lateral temp oral approach ; alth ough both resulted in excellent tumor expo sure on the ipsilateral side, contralateral ex pos ure was poor, making compl ete exc ision of the tum or difficult in cases of tum or ex tensio n. Oth er surgical approaches have been described, but regardl ess of the cho ice, the natur e of nasoph aryngeal ca rcino ma dem and s that the operation be tailored to the ind ividu al patient.
Nasopharyngectomy is an alternative treatm ent for local recu rrent and residual nasoph aryngeal carc inoma."
Treatment complications
Complication s of rad ioth erap y are fairl y we ll docum ented. Xerostom ia is the most commo n; others include pituitary dysfun ction , temp oral bone necro sis, dysphagia, cranial nerv e palsy, hearing loss, carotid artery stenosis , hypothyroidi sm , dry eye syndrome, myelit is, ence pha lopathy, hypopituitari sm , and seve re trismu s, to nam e a few. 29 . 34 Repeat irradiatio n has been associated with long-t erm problems with necro sis of the central nervous sys tem, bone, and soft tissue.
Most of the co mplications associated with cisplatin-based chemotherapy are bone marrow suppress ion, hearin g loss, and renal imp airment." Exper ienc e with chemo therapy is still limit ed, and studies with longer follow-up are requ ired.
Surgical complications can be divid ed into two ca tegories: those associated with nasopharyn gectomy and those asso ciated with neckd issection.t' Because surgery is usually perform ed after radi ation has been deli vered, complications related to poor wound healin g are co mmo n; they include palatal fistula, nasoph aryn geal wound infection, osteon ecrosis, nonunion or malun ion of osteotomy sites, and flap nec rosis. The most ser ious poten tial complications associated with resec tion of recurrent disease are dea th, caro tid artery rupture, and violation of the dura." Other possible complications are spec ific to the surg ical app roach ; amo ng them are maxillary nec rosis, choanal stenos is, saddle-nose deform ity, and trismu s.
Follow-up
Th e roles of direct and ind irect nasopharyngoscopy, CT, MRI , and molecul ar markers still need to be full y determin ed with res pect to survival and cost-effectiv eness. Frequent foll ow-up with biopsy of any suspicious residual or recurrent disea se is necessary.
• Some extensive reconstructi ve procedures-for exa mpie, laryngofi ssure, arytenoidectomy, voca l fold resect ion, and cordotomy-may result in a sec ure airway and closure of the tracheotomy site at the ex pense of voice quality.
• Long-term treatm ent and close follow-up are necessary in cases where scarring may progress and persist."
In conclusion, although there is so me controversy regarding the man agement of acute laryngotracheal traum a, treatm ent in ex perienced hand s will usually result in a favorabl e outcome."
